Kornimate/medical-research-clean huggingface dataset:
support for people undergoing chemotherapy

Conditions: Quality of Life; Cancer

Summary: chemotherapy adversely affects quality of life in cancer patients. both stress management training and exercise training have been shown to improve quality of life. these two types of training have not been directly compared for chemotherapy patients. this study seeks to evaluate the separate and combined effects of stress management training and exercise training on quality of life during chemotherapy treatment. participants receive either a home-based, self-administered program in 1 of 3 types (stress management, exercise, or stress management + exercise) or usual care (reading materials). it is hypothesized that the combined program (stress management + exercise) will be significantly associated with better quality of life than the usual care group, the exercise only group, and the stress management only group. all participants are assessed at 3 timepoints: before they begin chemotherapy, 6 weeks after their first chemotherapy infusion, and 12 weeks after their first infusion.


Eligibility criteria:
inclusion criteria: participants must: * be diagnosed with cancer * be scheduled to receive cytotoxic chemotherapy for at least 14 weeks * be ≥18 years of age or older * have an ecog performance status of 0, 1, or 2 * be capable of speaking and reading english * be able to provide informed consent exclusion criteria: * ecog of 3 or greater * presence of contraindications to participating in moderate intensity exercise including: 1. . metastases to weight-bearing sites (spine, pelvis, lower extremities) 2. . active infections 3. . cardiomyopathy or congestive heart failure 4. . severe pulmonary or ventilatory disease (fev 1.0\<50%) 5. . large pleural effusions or pericardial effusions 6. . anemia (hgb \<8g/dl) 7. . neutropenia (absolute neutrophil count \< 0.05 x 10(9th)/l) 8. . severe osteoporosis (\> 2.5 sd below age and gender norms) 9. . thrombocytopenia (platelets \< 20 x 10(9th)/l) 10. . hyponatremia (na+ \< 130 mmol/l) 11. . hypokalemia (k+ ≤ 3.0 mmol/l) 12. . hypercalcemia (ca++ \> 6.5 mmol/l) 13. . abnormal ecg 14. . sensorimotor deficits sufficient to impede unassisted walking * receipt of intravenous chemotherapy administration in the past 2 months * prescription for chronotropic, sympathomimetic, or inotropic/vasoactive medications * presence of other contraindications as determined by the attending oncologist and research staff

Keywords: stress management quality of life exercise cancer chemotherapy
i am able: population based rehabilitation in a family health team

Conditions: Chronic Conditions; Arthritis; Diabetes; Hypertension; Chronic Pain

Summary: people who have long-term conditions such as heart disease, diabetes, arthritis etc. face challenges in staying active and able to participate in activities that are important to them. there is some research that suggests that a care model that focuses on physical functioning and helping patients to manage their own conditions will assist them to stay active and healthy longer. in this project, the investigators are testing whether physiotherapy and occupational therapy offered to groups of patients and information about rehabilitation offered to other members of the health care team can help people with chronic conditions to maintain their physical abilities.

participants older than 44, with at least one chronic disease, (n=60) will participate in a before-and-after study integrating a population based, rehabilitation-focused program targeting physical function into a family health team. the program, delivered by a physiotherapist and occupational therapist, will consist of comprehensive functional assessments and individualized self-management care plans; a rehabilitation based chronic disease self-management program; and on-line self-monitoring of physical function. process and outcome measures will be administered at baseline and 4 months follow-up.

Eligibility criteria:
inclusion criteria: * 44 years and older * 1 or more chronic conditions * 3 visits to physician in the past year * access or willingness to access email exclusion criteria: * none
evaluation and classification of foot medial longitudinal arch height in adults

Conditions: Pes Planus

Summary: the aim of the study is, to evaluate and classificate the medial longitudinal arch height in adult individuals. aged between 18-40 years,350 adults who are voluntarily participate is going to be evaluate with feiss line(fl), navicular drop(nd) and longitudinal arch angle(laa) in subtalar neutral and resting position. maximum, minimum values are going to be calculated. the 95% and 68% prediction intervals will be used as cut off limits.

the aim of the study is, to evaluate and classificate the medial longitudinal arch height in adult individuals. aged between 18-40 years,350 adults who are voluntarily participate is going to be evaluate with feiss line(fl), navicular height(nh) and longitudinal arch angle(laa) in subtalar neutral and resting position. maximum, minimum values are going to be calculated. participant's height, weight and foot length, from posterior aspect of calcaneus to the longest toe's tip, will be measured. center of the medial malleolus, the navicular tuberosity and the head of the first metatarsal bone will be marked with a cd marker. with these landmarks in foot's relaxed position, neutrally, fl, nh and laa will be measured by a ruler. feiss line is a drawn line between the center of the medial malleolus to the head of the first metatarsal bone and then perpendicular line distance between this line and the navicular tuberosity will be drawn.the vertical line between the ground and the tubercle indicates navicular height. center of goniometer placed at the navicular tuberosity then goniometer arms follow the medial malleolus and the head of the first metatarsal bone, degree between two arms indicates longitudinal arch angle. fl, nh, laa mean values will be calculated. the 95% and 68% prediction intervals will be used as cut off limits.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-40 * individuals who voluntarily agree to participate in the study exclusion criteria: * those who have foot operation * foot trauma story which is causing an anatomic disorder

Keywords: feiss line medial longitudinal arch navicular drop pes planus
assessment of the pulmonary diffusion capacity in healthy infants and infants with chronic lung disease

Conditions: Infant, Premature; Bronchopulmonary Dysplasia; Asthma

Summary: the purpose of this study is to evaluate how easily gas can be taken up by the lung. we are comparing infants born premature \ 37 weeks. we hope to evaluate the differences between the two groups in order to learn more about premature lung growth and development.

we hypothesize that infants who were born prematurely but are clinically without chronic respiratory disease have a lower lung diffusion capacity than healthy infants born at full term, when evaluated at comparable post-conception ages. in addition, prematurely born infants that develop chronic lung disease have an even lower diffusion capacity than healthy premature infants and full term infants. a lower diffusion capacity, when normalized to lung volume, would be consistent with decreased alveolarization and alveolar surface area in the infants born prematurely. we will study the age range of 1 to 24 month as this represents the period of rapid lung growth.

Eligibility criteria:
inclusion criteria: * group 1 infants born at \< 32 weeks gestation with chronic lung disease * group 2 infants born at \<32 weeks gestation without chronic lung disease * group 3 infants born full term at \>37 weeks exclusion criteria: * group 1 and group 2--no heart disease, no oxygen requirement * group 3--no hospitalization for respiratory illness, no asthma, no heart disease, no history of wheezing, asthma or treatment with asthma medications.

Keywords: infant, premature bronchopulmonary dysplasia asthma
this study will investigate how food and age effect the way the body handles the azd5069 drug given as a oral dose

Conditions: Chronic Obstructive Pulmonary Disease

Summary: azd5069 is a new drug being tested for the possible treatment of people with chronic obstructive pulmonary disease (copd). this is not the first time that azd5069 will be administered to humans in clinical trials. we are conducting this study to determine whether azd5069 is safe and well tolerated by healthy males and females in fed and fasted states. we will compare the way the body handles this drug in the fed and fasted states, in subjects in the age group of 18 to 65 years. we will compare the way the body handles this drug between the age groups of 18 to 65 years and above 65 years. we will also be studying how quickly azd5069 is absorbed into and cleared by the body.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg. exclusion criteria: * has participated in another clinical study and received drug treatment within 3 months of the first administration of drug in this study. * subjects with a past medical history of tuberculosis (tb). * subjects with latent or chronic infections

Keywords: pharmacokinetics fasting or after a high fat meal adult elderly adult copd
evaluation of safety and efficacy of pivot balloon to monitoring acute rv failure and reduction of ftr

Conditions: Functional Tricuspid Regurgitation

Summary: pivot balloon to monitoring acute rv failure and reduction of functional tricuspid regurgitation

the study for evaluation of safety and efficacy of pivot balloon to monitoring acute rv failure and reduction of functional tricuspid regurgitation : multi-center, open label, single arm, investigator initiated exploratory pilot study

Eligibility criteria:
inclusion criteria: * adult males and females aged 20 years or above * target of thoracic surgery for tr and patients above the severe level on the criteria presented in the classification of tr grade based on echocardiogram, among those with tr, for whom a surgical treatment has been decided * an individual who voluntarily agreed to the participation in the clinical trial and signed the written consent * an individual who is able to understand and comply with the instructions and who can participate in the period before the clinical trial exclusion criteria: * uncontrolled hyperthyroidism * a recent formation of soft blood clot or embolic material * uncorrected coagulopathy * prohibition of anticoagulant agents * previous insertion of a device such as an implantable cardioverter defibrillator (icd) or a pacemaker * presence of malignant tumor or benign tumor such as myxoma in the heart * presence of a symptom of active infection * chronic pulmonary disease * congenital tricuspid valve insufficiency * pregnant or lactating mother, or a female patient planning pregnancy during the period of clinical trial, or a female not using an approved contraceptive with the possibility of pregnancy * participation in another clinical trial 30 days prior to the screening * in addition, anyone showing a clinical finding deemed to be unsuitable for the clinical trial by the principal investigator or the investigator

Keywords: ftr rv failure taupnu
the linfu® u.s. registry in patients with clinical signs and/or symptoms of disease

Conditions: Pancreatic Cancer; Jaundice; Abdominal Neoplasm

Summary: evaluate linfu® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (pdac) or have evidence of imaging studies suggestive of pdac.

adenocyte has developed a proprietary pancreatic cancer detection method, linfu®, (low intensity non-focused ultrasound excitation of the pancreas) that increases the sensitivity of pancreatic juice cytology. linfu® excitation of circulating microbubbles increases the exfoliation of pancreatic ductal cells. the sensitivity of cytological examination of the pancreatic fluid obtained by linfu® can also be potentially enhanced by neural network-based computer-assisted analysis. in this study, linfu® will be evaluated in patients who exhibit symptoms suggestive of pdac (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) or have evidence of imaging studies suggestive of pdac. in addition, patients with pdac identified only with linfu® and not detected with other diagnostic tests will be followed long term to determine the progression rate of these tumors and to determine whether linfu® results in earlier intervention, treatment and improvement in patient outcomes.

Eligibility criteria:
inclusion criteria: * both males and females will be enrolled and must be at least 18 years of age and under age of 90 * patients, who in the opinion of the investigator, require biopsy to rule out pdac because they display at least one of the following or both: a) clinical symptoms of pdac including jaundice, nausea and vomiting, weight loss, abdominal pain, bloating or the feeling of fullness, itchy skin, lower back pain, light-colored, greasy stools, sudden onset type 2 diabetes, etc. b) one or more imaging studies suggestive of pdac * all patients must undergo contemporaneous imaging, either within 90 days before the linfu® procedure or within 30 days after the procedure, with one or more of the following: eus± fna, mri/mrcp, ercp, ct or ceus. * institutional review board (irb)-approved consent must be signed by patients to participate in this study. exclusion criteria: * patient under the age of 18 and over the age 90 * contraindications to linfu®/eus/ercp as determined by study investigators: patient with uncorrectable coagulopathy; patient that cannot undergo anesthesia due to cardiopulmonary contraindication as deemed by the anesthesiologist; unstable medically (cardiopulmonary, neurologic, or cardiovascular status) * patients undergoing eus or ercp for a suspected bile duct cancer arising from the intrahepatic or extrahepatic biliary epithelium * patients who are already known to have pdac by cytologic or histologic evidence * patients with intraductal papillary mucinous neoplasm of the pancreas (ipmn) identified either before the study or during the study through imaging evaluation will be excluded * pregnant females will be excluded * patient that is unable to provide informed consent * patient with known allergy to the microbubble contrast agent or secretin
outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Summary: this study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. collecting information from patients before, during, and after receiving chimeric antigen receptor therapy or radiation therapy may help doctors to optimize patient selection, dose, timing, and sequencing of these treatments.

primary objective: i. record clinical outcomes of patients with hematologic malignancies receiving standard-of-care chimeric antigen receptor therapy (car-t) nd/or standard-of- care bispecific therapy, and radiation therapy (rt). secondary objectives: i. to record patient-specific factors and treatment-related factors in patients with hematologic malignancies receiving standard-of-care car-t, and/or standard-of-care bispecific therapy, and rt to ultimately improve patient selection and overall treatment strategy to optimize clinical outcomes. ii. to record and explore the relationship between radiation dose, target, technique, and timing with respect to car-t, and/or standard-of-care bispecific therapy and clinical outcomes in patients with hematologic malignancies treated with standard-of-care car-t, and/ or standard-of-care bispecific therapy, and rt. iii. to record and study the relationship between patient-specific factors and treatment-related factors and treatment toxicity in patients with hematologic malignancies undergoing standard-of-care car-t, and/or standard-of-care bispecific therapy, and rt. outline: patients medical records are reviewed for details about car-t and rt treatment and acute and late toxicities, disease outcomes such as any events related to local or distant disease progression, survival, and cause of death if available. patients' imaging scan data is collected at baseline, within 2 months of the first treatment of rt or car-t, and at 3, 6, 12 months, and then annually for 5 years after rt completion.

Eligibility criteria:
inclusion criteria: * age 18 years or older * treatment with or intention to treat with radiation therapy, standard-of-care car-t cell therapy and/or standard-of-care bispecific therapy, within a 90 day window for a hematologic malignancy
mk0767 and metformin combination study (0767-028)

Conditions: Diabetes Mellitus

Summary: a study to test the effects of mk0767 when added to metformin in patients with inadequately controlled type 2 diabetes mellitus. this is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (full information is available to trial participants).


Eligibility criteria:
inclusion criteria: * all women of childbearing potential must have a negative urine pregnancy test prior to starting the study * patients must be on a stable dose of metformin for at least 2 weeks prior to visit 2 exclusion criteria: * patients with a history of type 1 diabetes mellitus and/or history of ketoacidosis * patients on estrogen replacement therapy regimen or serm * patients with history of, allergy to, intolerance or hypersensitivity to statins or fibric acid derivatives, including history of elevated muscle and liver function tests, jaundice, hepatoxicity, or myopathy associated with these treatments * patient is on a weight loss program with ongoing weight loss or starting an intensive exercise program within 4 weeks from starting the study * have active liver or gall bladder disease * hiv positive
university of virginia natural history study

Conditions: Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Sarcoidosis; Connective Tissue Diseases; Hypersensitivity Pneumonitis; Idiopathic Interstitial Pneumonias

Summary: data and specimens will be collected longitudinally from patients seen in the uva interstitial lung disease (ild) clinic in order to describe the phenotypic expression of various interstitial lung diseases. samples will also be collected from a control group for comparison purposes. all data will be entered into a repository for future research purposes or screening for new studies that become available. this data will help identify trends and hopefully lead to a better understanding of the disease progression, treatment options, and outcomes.

following the clinical course of patients with ild will allow description of the natural history of these diseases and prospective analysis of the following specific questions: 1. can surrogate physiological markers of disease progression be used in place of mortality? mortality of a defined cohort of patients will be developed. the surrogate markers include but are not limited to serial cardiopulmonary exercise testing, pulmonary function testing, 6-minute walk testing, hrct scanning and echocardiography. 2. do alternative assessments such as quality of life (qol) questionnaires provide early prediction of physiological change as measured by the previously described parameters? periodic qol questionnaires are regularly conducted in clinic and will be followed 3. does rate of deterioration as measured by these previously described parameters affect response to therapy? if we pre-identify rapid decliners from stable subjects, does this variable affect the response to whatever therapy is applied? 4. can genetic analysis, genomics, proteomics, microbial and other biomarkers in the blood and cheeks provide insight into the polymorphisms and other elements related to the etiology and pathology of the lung damage?

Eligibility criteria:
inclusion criteria: * patient presenting to university of virginia ild or pulmonary clinic * family members accompanying patients (as control subjects) exclusion criteria: * control subjects cannot have ild
autobiographical memory

Conditions: Alzheimer's Disease; Autobiographical Memory; Eye Movement; Memory

Summary: this study aims at the assessment of eye movement during autobiographical retrieval (i.e., retrieval of personal memories) in patients with alzheimer's disease.

there is an increased interest in the study of eye movements during the retrieval of autobiographical memories and recent research has demonstrated how retrieval of autobiographical memory can activate eye movement. this research has been however mainly concerned with young adults and, until now, little is known about the relationship between eye movement and autobiographical memory in patients with alzheimer's disease. the aim of the current study is therefore to evaluate eye movements during the retrieval of autobiographical memories in patients with alzheimer's disease.

Eligibility criteria:
inclusion criteria : * diagnosis of alzheimer's disease at the mild stage exclusion criteria : * neurological/psychiatric disorders (other than alzheimer's disease)
assessment of exposures of the mother-infant pair to the air pollution of são paulo

Conditions: Lung Diseases

Summary: a single group of pregnant women who was analyzed in the first and in the third trimesters of pregnancy

a single group of 120 pregnant women separated in smokers (n = 17) and nonsmokers (n = 103) and first pregnancy (n = 54) or multiparous (n = 66) who underwent pulmonary function test and used the individual passive sampler in the first and third trimesters of pregnancy

Eligibility criteria:
inclusion criteria: * prior informed consent; * single pregnancy; * topical and feasible; * gestational age of less than 13.86 weeks at the first evaluation; * absence of preexisting maternal diseases exclusion criteria: * withdrawal from the project; * abortion; * inadequate pulmonary function test

Keywords: respiratory function tests air pollution pregnancy spirometry